达沙替尼不同治疗方案治疗慢性髓细胞白血病疗效的Meta分析郭敏.pdfVIP

• 2012, 12(7): 785790 * 730000 140 mgqd 70 mgbid chronic myeloid leukemiaCML EMbase 1974 2011.11PubMed 1966 2011.11Cochrane Library 2011 11 CBM 1979 2011.11VIP 1989 2011.11CNKI 1994 2011.11WanFang Data 1997 2011.11140 mgqd 70 mgbid CML RCTCochrane RevMan 5.1 Meta 4 2 862 Meta 140 mgqd 70 mgbid CML RR=0.9795%CI 0.881.07P=0.58RR=0.9495%CI 0.801.11P=0.47 RR=0.9995%CI 0.861.13P=0.86CML CP- CMLRR=0.9995%CI 0.901.07P=0.73RR=0.9995%CI 0.78 1.26P=0.95RR=1.0195%CI 0.831.22P=0.95 CML 140 mg 70 mg CML Meta Ef ectiveness of Dif erent Regimes of Dasatinib for Chronic Myeloid Leukemia: A Meta-Analysis * GUO Min, XI Ya-ming , CHAO Rong, ZHAO Long, JIN Rui-rui Institute of Hematology and Department of Hematology, the First Clinical Hospital of Lanzhou University, Lanzhou 730000, China Abstract Objective To systematically evaluate the ef ectiveness of dasatinib in doses of 140 mg once daily and 70 mg twice daily for chronic myeloid leukemia (CML). Methods h e randomized controlled trials (RCTs) were re- trieved from Embase (1974 to November 2011), Pubmed (1966 to November 2011), The Cochrane Library (Issue 11, 2011), CBM (1979 to November 2011), VIP (1989 to November 2011), CNKI (1994 to November 2011), Wanfang Data (1997 to November 2011) and references listed in all articles. RCTs meeting inclusive criteria were included, the data were extracted, the quality was evaluated and cross-checked by two reviewers independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then meta-analyses were conducted using RevMan 5.1 sot ware. Results A total of four studies involving two RCTs and 862